提供支持According to 36Kr.com, ThunderBio Life Sciences Technology Co., Ltd. ("ThunderBio") has raised 10 million yuan in its angel round of financing, with a total of ￥20M in funding rounds. Proceeds from this financing will be used to the marketing of the Nebula Digital PCR System, ThunderBio's first microfluidic product.
ThunderBio was incubated in the Hong Kong University of Science and Technology in 2017 and is lovated in the Zhejiang Jiashan Industrial New Town. ThunderBio focuses on the development of the in vitro diagnostic platform based on microfluidic technology. At present, the company has 16 domestic and foreign patents either authorized or declared. It has a research and development center for instruments, reagents and chips, with another chip production workshop to be used for mass production in the second quarter of 2020.
ThunderBio uses microfluidic chips and "water-in-oil" technology to solve the problems of digitalization and precision, turning the only one result from original detection into 100,000 data that are digitized and visualized.
The digital PCR system developed by ThunderBio can digitize the results of traditional medical tests, which can be used for medication guidance or pre-treatment. The first series of the digital PCR system will be on the market in the second quarter of 2020. Currently, the products are undergoing the approval of CE mark certification.
In recent years, the digital PCR system has been widely used in many fields such as liquid biopsy and tumor detection. The market for liquid biopsies is expected to be worth $22 billion by 2020, according to the BCC. The market capacity in China is also expected to be 20 billion yuan.
Zhou Guohui, the co-founder and CEO of ThunderBio, said that the company will invest more in technology and resources to develop ultra-sensitive detection equipment, such as single-molecule protein detection, microflow chemiluminescence and POCT instruments, to discover new applications for IVD detection.
渝公网安备 50011202502165号
